ZEISS Vision Care has acquired a 10% stake in Ocumeda for €10 million, enhancing its commitment to advancing tele-ophthalmology across Europe.

Target Information

Ocumeda AG is Europe's leading tele-ophthalmology platform, dedicated to preventing vision loss and blindness for millions of individuals. Established by a multidisciplinary team of renowned ophthalmologists, Ocumeda was founded in response to the frequent occurrence of late diagnoses in severe eye diseases, which often resulted in irreversible vision impairment. The company’s mission is to make eye care accessible to everyone, and so far, it has examined approximately 300,000 patients through a network of over 700 optical retailers and eye care professionals.

Recently, ZEISS Vision Care announced its acquisition of a 10% stake in Ocumeda from the Fielmann Group for €10 million, setting Ocumeda's total company valuation at €100 million. This partnership is poised to expand Ocumeda's open platform across Europe in collaboration with the Fielmann Group.

Industry Overview

The tele-ophthalmology sector in Europe is rapidly evolving, driven by advancements in technology and a growing awareness of the importance of eye health. With the increasing prevalence of vision-related issues, the demand for access